Symbicort ups small airway function; study
Anglo-Swedish drug major AstraZeneca presented results from studies evaluating the maintenance combination asthma therapy Symbicort (budesonide/formoterol fumarate) that showed significant improvement in small airway function in patients with asthma, at the American Academy of Allergy, Asthma & Immunology annual meeting held in Washington DC.
The two 12-week, randomized, double-blind, double-dummy studies enrolled 1,076 patients aged 12 years and older with asthma who had previously received inhaled corticosteroid maintenance therapy.
Results from Study I showed that Symbicort produced significantly-greater improvements (P<0.05) in pre-dose lung function compared to formoterol and placebo (FEF25-75% - forced expiratory flow during the middle half of exhalation, a measure of small airway obstruction). FEF25-75% declined over 12 weeks for patients receiving formoterol and placebo. Patients receiving Symbicort and budesonide had similar improvements in FEF25-75% that were maintained over 12 weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze